Riboflavin status, MTHFR genotype and blood pressure: Current evidence and implications for personalised nutrition

Proceedings of the Nutrition Society

Volumn 75, Issue 3, 2016, Pages 405-414

  McAuley, E ^a   McNulty, H ^a   Hughes, C ^a   Strain, J J ^a   Ward, M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Blood pressure; Methylenetetrahydrofolate reductase; MTHFR C677T; Personalised nutrition; Riboflavin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; FLAVINE ADENINE NUCLEOTIDE; RIBOFLAVIN; FOLIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ABSORPTION; AGE; ANTIHYPERTENSIVE ACTIVITY; AUSTRALIA; BLOOD PRESSURE; BODY TEMPERATURE; CARBON METABOLISM; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DOSE RESPONSE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EUROPE; FOOD COMPOSITION; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENOTYPE; GERMANY; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MTHFR GENE; NETHERLANDS; NEURAL TUBE DEFECT; NEW ZEALAND; NITROGEN BALANCE; NONHUMAN; NORTH AMERICA; NUTRIGENOMICS; NUTRITION; PATHOGENESIS; PERSONALIZED NUTRITION; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIBOFLAVIN DEFICIENCY; SEX DIFFERENCE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; UNITED KINGDOM; UNITED STATES; URINARY EXCRETION; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; GENETICS; HOMOZYGOTE; IRELAND; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BIOMARKERS; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; GENOTYPE; HOMOZYGOTE; HUMANS; IRELAND; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NUTRITIONAL REQUIREMENTS; NUTRITIONAL STATUS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBOFLAVIN; RIBOFLAVIN DEFICIENCY; RISK FACTORS; UNITED KINGDOM;

EID: 84966642548     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665116000197     Document Type: Conference Paper

References (124)

1. Food and Nutrition Board, Institute of Medicine (1998) Riboflavin. In Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Vitamin B12, Pantothenic Acid, Biotin, and Choline, pp. 87-122 [RM Pitkin, editor]. Washington, DC: National Academy Press.
2. Wilcken B, Bamforth F, Li Z et al. (2003) Geographical and ethnic variation of the 677CT allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40, 619-625.
3. Klerk M, Verhoef P, Clarke R et al. (2002) MTHFR 677CT polymorphism and risk of coronary heart disease-a meta-analysis. JAMA 288, 2023-2031.
4. Yang B, Fan S, Zhi X et al. (2014) Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS ONE 9, e87497.
5. Horigan G, McNulty H, Ward M et al. (2010) Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677CT polymorphism in MTHFR. J Hypertens 28, 478-486.
6. Wilson CP, Ward M, McNulty H et al. (2012) Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y followup. Am J Clin Nutr 95, 766-772.
7. Wilson CP, McNulty H, Ward M et al. (2013) Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension 61, 1302-1308.
8. McCormick DB (2006) Riboflavin. In Modern Nutrition in Health and Disease, 10th ed., pp. 391-399 [ME Shils, editor]. New York: Williams & Wilkins.
9. Powers HJ (1999) Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Proc Nutr Soc 58, 435-440.
10. Powers HJ, Weaver LT, Austin S et al. (1993) A proposed intestinal mechanism for the effect of riboflavin deficiency on iron loss in the rat. Br J Nutr 69, 553-561.
11. Powers HJ, Hill MH, Mushtaq S et al. (2011) Correcting a marginal riboflavin deficiency improves hematologic status in young women in the United Kingdom (RIBOFEM). Am J Clin Nutr 93, 1274-1284.
12. Powers HJ (1995) Riboflavin-iron interactions with particular emphasis on the gastrointestinal tract. Proc Nutr Soc 54, 509-517.
13. McCormick DB (1989) Two interconnected B vitamins: riboflavin and pyridoxine. Physiol Rev 69, 1170-1198.
14. Rasmussen KM, Barsa PM & McCormick DB (1979) Pyridoxamine (pyridoxine) 5?-phosphate oxidase activity in rat tissues during development of riboflavin or pyridoxine deficiency. Proc Soc Exp Biol Med 161, 527-530.
15. Madigan SM, Tracey F, McNulty H et al. (1998) Dietary intake and status of riboflavin and vitamin B6 and biochemical response to riboflavin supplementation in free living elderly people. Am J Clin Nutr 68, 389-395.
16. Powers HJ (2003) Riboflavin (vitamin B-2) and health. Am J Clin Nutr 93, 1274-1284.
17. Said HM & Mohammadkhani R (1993) uptake of riboflavin across the brush border membrane of rat intestine: regulation by dietary vitamin levels. Gastroenterology 105, 1294.
18. Sauberlich HE, Skala JH & Dowdy RP (1974) Laboratory Tests for the Assessment of Nutritional Status. Boca Raton, FL: CRC Press.
19. McCormick DB (1990) Riboflavin. In Present Knowledge in Nutrition, 6th ed., pp. 146. Washington, DC: International Life Sciences Institute.
20. Rivlin RS (1991) Disorders of vitamin metabolism: deficiencies, metabolic abnormalities and excesses. In Cecil Textbook for Medicine, 19th ed., pp. 1170 [JH Wyngaarden, LH Jr Smith, JC Bennett and F Plum, editors]. Philadelphia: WB Saunders.
21. Pinto JT, Huang JP & Rivlin RS (1987) Mechanisms underlying the different effects of ethanol upon the bioavailability of riboflavin and flavin adenine dinucleotide. J Clinc Invest 78, 1343.
22. Yuasa H, Hirobe M, Tomei S et al. (2000) Carrier-mediated transport of riboflavin in the rat colon. Biopharm Drug Dispos 21, 77-82.
23. Scientific Committee for Food (1993). Nutrient and Energy Intakes for European Community. (Opinion expressed on 11 December 1992). Thirty-first Series of Reports of the Scientific Committee for Food. Luxembourg: Commission of the European Communities.
24. Department of Health (1991) Dietary Reference Values for Food, Energy and Nutrients for the United Kingdom. London: HMSO.
25. Food and Nutrition Board, Institute of Medicine (1998) Dietary Reference Intakes for Thiamine, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Washington, DC: National Academy Press; 1998.
26. Scientific Committee for Food (2000). Nutrient and Energy Intakes for European Community. (Opinion Expressed on 22 November 2000). Thirty-third Series of Reports of the Scientific Committee for Food. Brussels: Commission of the European Communities.
27. Bates B, Lennox A, Bates C et al. (2014) National Diet and Nutrition Survey: Results from Years 1-4 (combined) of the Rolling Programme (2008/2009-2011/12). London: Public Health England and the Food Standards Agency.
28. Allen L, de Benoist B, Dary O et al. (2006) Guidelines on Food Fortification with Micronutrients. Geneva, Switzerland: World Health Organisation and Food and Agriculture Organisation of the United Nations.
29. McCormick DB (1994) Riboflavin. In Modern Nutrition in Health and Disease, 8th ed., pp. 366 [ME Shils, JE Olsen and MM Shike, editors]. Philadelphia.
30. Food and Nutrition Board. Institute of Medicine (2000) Riboflavin. In Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, biotin and Choline, pp. 87 [RM Pitkin, editor]. Washington, DC: National Academy Press.
31. Rivlin RS (1979) Effect of nutrient toxicities (excess) in animals and man: riboflavin. In Handbook of Nutrient and Foods, p. 25. [M Recheigl, editor]. Boca Raton: CRC Press.
32. Cooperman JM & Lopez R (1984) Riboflavin. In Handbook of Vitamins: Nutritional, Biochemical and Clinical Aspects, p. 299 [J Machlin, editor]. NY: Marcel Dekker.
33. Zempleni J, Galloway JR & McCormick DB (1996) Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 63, 54-66.
34. Cimino JA et al. (1987) Riboflavin metabolism in the hypothyroid human adult. Proc. Soc Exp Biol Med 184, 121.
35. Apeland T, Mansoor MA, Pentieva K et al. (2003) Fasting and post methionine load concentrations of homocysteine, vitamin B2 and vitamin B6 in patients on antiepileptic drugs. Clinical Chemistry 49, 1005-1008.
36. Dutta P, Pinto JT & Rivlin RS (1985) Antimalarial effects of riboflavin deficiency. Lancet 2, 1040.
37. Bates CJ, Prentice AM, Paul AA et al. (1982) Riboflavin status in infants born in rural Gambia, and the effects of a weaning food supplement. Trans R Soc Trop Med Hyg 76, 253-258.
38. Tan KL, ChowMT & Karim SMM (1978) Effect of phototherapy on neonatal riboflavin status. J Pediatr 78, 780-781.
39. Wacker J, Fruhauf J, Schulz M et al. (2000) Riboflavin deficiency and preeclampsia. Obstet Gynecol 96, 38-44.
40. Wu XM, Yang KX, Tang XD et al. (2015) Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis. J Assist Reprod Genet 32, 797-805.
41. Belko AZ, Obarzanek E, Roach R et al. (1984) Effects of aerobic exercise and weight loss on riboflavin requirements of moderately obese, marginally deficient young women. Am J Clin Nutr 40, 553-561.
42. Soares MJ, Satyanarayana K, Bamji MS et al. (1993) the effect of exercise on the riboflavin status of adult men. Br J Nutr 69, 541-551.
43. Benton D, Haller J & Fordy J (1997) The vitamin status of young British adults. Int J Vitam Nutr Res 67, 34-40.
44. Hoey L, McNulty H & Strain JJ (2009) Studies of biomarker responses to intervention with riboflavin: a systemic review. Am J Clin Nutr 89, 1960S-1980S.
45. Pan W-H, Chang Y-P, Yeh W-T et al. (2012) Co-occurrence of anemia, marginal vitamin B6, and folate status and depressive symptoms in older adults. J Geriatr Psychiatry Neurol 25, 170-178.
46. Hill MHE, Bradley A, Mushtaq S et al. (2009) Effects of methodological variation on assessment of riboflavin status using the erythrocyte glutathione reductase activation coefficient assay. Br J Nutr 102, 273-278.
47. Clements JE & Anderson BB (1980) Glutathione reductase activity and pyridoxine (pyridoxamine) phosphate oxidase activity in the red cell. Biochim Biophys Acta 632, 159-163.
48. Chastain JL & McCormick DB (1987) Flavin catabolites: identification and quantitation in human urine. Am J Clin Nutr 46, 830.
49. Horwitt MK, Harvey CC, Hills OW et al. (1950) Correlation of urinary excretion of riboflavin with dietary intake and symptoms of ariboflavinosis. J Nutr 42, 247-264.
50. Hustad S, Ueland P, Vollset S et al. (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 46, 1065-1071.
51. Jacques PF, Kalmbach R, Bagley PJ et al. (2002) The relationship between riboflavin and plasma total homocysteine in the Framingham offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 132, 283-288.
52. Hustad S, McKinley MC, McNulty H et al. (2002) Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation. Clin Chem 48, 1571-1577.
53. Preziosai P, Galan P, Deheeger M et al. (1999) breakfast type, daily nutrient intakes and vitamin and mineral status of French children, adolescents, and adults. J Am Coll Nutr 18, 171-178.
54. Matrix J, Aranda P, Sanchez C et al. (2003) Assessment of thiamin (vitamin B1) and riboflavin (vitamin B2) status in an adult Mediterranean population. Br J Nutr 90, 661-666.
55. Troesch B, Hoeft B, McBurney M et al. (2012) Dietary surveys indicate vitamin intakes below recommendations are common in representative Western countries. Br J Nutr 108, 692-698.
56. ter Borg S, Verlaan S, Hemsworth J et al. (2015) Micronutrient intakes and potential inadequacies of community-dwelling older adults: a systematic review. Br J Nutr 113, 1195-1206.
57. Shi Z, Zhen S, Wittert GA et al. (2014) Inadequate riboflavin intake and anemia risk in a Chinese population: five-year follow up of the Jiangsu Nutrition Study. PLoS ONE 9, e88862.
58. Ministry of Health and Welfare Korea Centers for Disease Control and Prevention (2013) Korea Health Statistics 2010-2012: Korea National Health and Nutrition Examination Survey (KNHANES V-3). Osong, Korea: Korea Centers for Disease Control and Prevention.
59. Choi JY, Kim YN & Cho YO (2015) Evaluation of riboflavin intakes and status of 20-64 year old adults in South Korea. Nutrients 7, 253-264.
60. Brun TA, Campbell TC, Boreham J et al. (1990) Urinary riboflavin excretion after a load test in rural China as a measure of possible riboflavin deficiency. Eur J Clin Nutr 44, 195-206.
61. Abrams SA, Mushi A, Hilmers DC et al. (2003) A multinutrient-fortified beverage enhances the nutritional status of children in Botswana. J Nutr 133, 1834-1840.
62. Boisvert WA, Castaneda C, Mendoza I et al. (1993) Prevalence of riboflavin deficiency among Guatemalan elderly people and its relationship to milk intake. Am J Clin Nutr 58, 85.
63. Yang FL, Liao PC, Chen YY et al. (2005) Prevalence of thiamin and riboflavin deficiency among the elderly in Taiwan. Asia Pac J Clin Nutr 14, 238-243.
64. Whitfield K, McCann A, Karakochuk C et al. (2015) High rates of riboflavin deficiency in women of childbearing age in Cambodia and Canada. J Nutr 145, 628-633.
65. Frosst P, Blom HJ, Milos R et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113.
66. Guenther BD, Sheppard CA, Tran P et al. (1999) The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocystaemia. Nat Struct Biol 6, 359-365.
67. Yamada K, Chen Z, Rozen R et al. (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 98, 14853-14858.
68. Narisawa K, Tamura T, Tanno K et al. (1968) Tetrahydro-folate-dependent enzyme activities of the rat liver in riboflavin deficiency. Tohoku J ExpMed 94, 417-430.
69. Bates CJ & Fuller NJ (1986) The effect of riboflavin deficiency on methylenetetrahyfrofolate reductase (NADPH) (EC 15120) and folate metabolism in the rat. Br J Nutr 55, 455-464.
70. McNulty H, Dowey le RC, Strain JJ, et al. (2006) Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677CT polymorphism. Circulation 113, 74-80.
71. McNulty H, McKinley MC, Wilson B et al. (2002) Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 76, 436-441.
72. Garcia-Minguillan CJ, Fernandez-Ballart JD, Ceruelo S et al. (2014) Riboflavin status the effects of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms on homocysteine. Genes Nutr 9, 435.
73. Wald DS, Law M & Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325, 1202.
74. Holmes MV, Newcombe P, Hubacek JA et al. (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378, 584-594.
75. Lewis SJ, Ebrahim S & Davey Smith G (2005) Meta-analysis of MTHFR 677CT polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 331, 1053.
76. Klerk M, Verhoef P, Clarke R et al. (2002) MTHFR 677CT polymorphism and risk of coronary heart disease-a meta-analysis. JAMA 288, 2023-2031.
77. Wald DS, Morris JK & Wald NJ (2011) Reconciling the evidence on serum homocysteine and ischemic heart disease: a meta-analysis. PLoS ONE 6, e16473.
78. Clarke R, Bennett DA, Parish S et al. (2012) Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 9, e1001177.
79. Lim SS, Vos T & Flaxman AD (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224-2260.
80. Lewington S, Clarke R, Qizilbash N et al. (2002) Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913.
81. Whelton PK, He J, Appel LJ et al. (2002) Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 288, 1882-1888.
82. Luft FC (2001) Twins in cardiovascular genetic research. Hypertension 37, 350-356.
83. Mongeau JG (1987) Heredity and blood-pressure in humans-an overview. Pediatr Nephrol 1, 69-75.
84. Tomaszewski M, Debiec R, Braund PS et al. (2010) Genetic architecture of ambulatory blood pressure in the general population insights from cardiovascular genecentric array. Hypertension 56, 1069-1076.
85. Levy D, Ehret GB, Rice K et al. (2009) Genome-wide association study of blood pressure and hypertension. Nat Genet 41, 677-687.
86. Newton-Cheh C, Johnson T, Gateva V et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41, 666-676.
87. Takeuchi F, Isono M, Katsuya T et al. (2010) Blood pressure and hypertension are associated with 7 Loci in the Japanese population. Circulation 121, 2302-2309.
88. Markan S, Sachdeva M, Sehrawat BS et al. (2007) MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians. Mol Cell Biochem 302, 125-131.
89. Liu C, Li H, Qi Q et al. (2011) Common variants in or near FGF5, CYP17A1 and MTHFR genes are associated with blood pressure and hypertension in Chinese Hans. J Hypertens 29, 70-75.
90. Flister MJ, Tsaih SW, O'Meara CC et al. (2013) Identifying multiple causative genes at a single GWAS locus. Genome Res 23, 1996-2002.
91. Heux S, Morin F, Lea RA et al. (2004) The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 27, 663-667.
92. Jiang S, Hsu YH, Xu X et al. (2004) The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 113, 361-369.
93. Nishio H, Lee H, FujiiMet al. (1996) A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population Japanese. J Hum Genet 41, 247-251.
94. Bayramoglu A, Kucuk M, Guler HI et al. (2015) Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension? Cytotechnology 67, 115-122.
95. Benes P, Kankova K, Muzik J et al. (2001) Methylenetetrahydrolfolate reductase polymorphism, type II diabetes mellitus, coronary artery disease, and essential hypertension in the Czech population. Mol Genet Metab 73, 188-195.
96. Inamoto N, Katsuya T, Kokubo Y et al. (2003) Association of methlenetetrahydrolfolate reductase gene polymorphism with carortid atherosclerosis depending on smoking status in Japanese general population. Stroke 34, 1628-1633.
97. Guillen M, Corella O, Portoles JI et al. (2001) Prevalence of the methylenetetrahydrofolate reductase 677C>T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol 17, 255-261.
98. Nakata Y, Katsuya T, Takami S et al. (1998) Methylenetetrahydrofolate reductase gene polymorphism-relation to blood pressure and cerebrovascular disease. Am J Hypertens 11, 1019-1023.
99. Fowdar YJ, Lason MV, Szvetko AL et al. (2012) Investigation of homocysteine-pathway-related variants in essential hypertension. Int J Hypertens 2012, 190923.
100. Rodriguez-Esparragon F, Hernandez-Perera O, Rodriguez-Perez JC et al. (2003) The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 25, 209-220.
101. Reilly R, McNulty H, WardMet al. (2013) The MTHFR 677TT genotype and its interaction with related B-vitamins in hypertension. Ann Nutr Metab 63, 160.
102. Antoniades C, Shirodaria C, Warrick N et al. (2006) 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation 114, 193-201.
103. Antoniades C, Shirodaria C, Leeson P et al. (2009) MTHFR 677 C-T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 119, 2507-2515.
104. Bagley PJ & Selhub J (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95, 13217-13220.
105. Strain JJ, Hughes CF, McNulty H et al. (2015) Riboflavin lowers blood pressure: a review of a novel gene-nutrient interaction. Nutr Food Sci Res 2, 3-6.
106. Kaput J (2008) Nutrigenomics research for personalised nutrition and medicine. Curr Opin Lipid 19, 1-11.
107. Ronteltap A, van Trijp H, Berezowska A et al. (2013) Nutrigenomics-based personalised nutritonal advice: in search of a business model? Genes Nutr 8, 153-163.
108. Makeeva OA, Markova VV, Roses AD et al. (2010) An epidemiologic-based survey of public attitudes towards predictive genetic testing in Russia. Person Med 7, 291-300.
109. Joost H, GibneyM, Cashman K et al. (2007) Personalised nutrition: status and perspectives. Br J Nutr 98, 26-31.
110. Cherkas LF, Harris JM, Levinson E et al. (2010) A survey of UK public interest in internet-based personal genome testing. PLoS ONE 5, e13473.
111. Stewart-Knox B, Bunting B, Gilpin S et al. (2008) Attitudes toward genetic testing and personalised nutrition in a representative sample of European consumers. Br J Nutr 101, 982-989.
112. Aro AR, Hakonen A, Hietala M et al. (1997) Acceptance of genetic testing in a general population: age, education and gender differences. Patient Educ Couns 32, 41-49.
113. Bloss CS, Schork NJ & Topol EJ (2011) Effect of direct-to-consumer genome wide profiling to assess disease risk. N Engl J Med 364, 524-534.
114. McBride CM, Koehly LM, Sanderson SC et al. (2010) The behavioral response to personalised genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behavours? Patient Educ Couns 31, 89-103.
115. Norrgard K (2008) DTC genetic testing for diabetes, breast cancer, heart disease and paternity. Nat Educ 1, 1.
116. Qian X, Zhiagang L, Miao T et al. (2007) A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 15, 1239-1245.
117. Niu WQ, You YG, Qi Y et al. (2012) Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertensionin-pregnancy in Chinese: a meta-analysis. J Hum Hypertens 26, 259-267.
118. Wu YL, Hu CY, Lu SS et al. (2014) Associations between methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and essential hypertension: a systematic review and meta-analysis. Metabolism 63, 1503-1511.
119. Yang KM, Jia J, Mao L et al. (2014) Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: a meta-analysis of 10, 415 subjects. Biomed Rep 2, 699-708.
120. Bouwman L, te Molder H & Hiddink G (2008) Patients evidence and genes: an exploration of GPs' perspectives on gene-based personalised nutrition advice. Fam Pract 25, l116-l122.
121. Bonter K, Desjardins C, Currier N et al. (2011) Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family practice. BMJ Open 1, e000110.
122. Weir M, Morin K, Ries N et al. (2010) Canadian health care professionals' knowledge, attitudes and perceptions of nutritional genomics. Br J Nutr 104, 1112-1119.
123. Pirzadeh-Miller S, Bellcross C, Robinson C et al. (2011) Direct-to-consumer genetic testing: helpful, harmful, or pure entertainment? Commun Oncol 8, 263-268.
124. Cherkas LF, Harris JM, Levinson E et al. (2010) A survey of UK public interest in internet-based personal genome testing. PLoS ONE 5, e13473.